The forecast for antihypertensive medicine sales in Canada from 2024 to 2028 highlights a consistent value of USD 2.8 per capita, following an increase from USD 2.7 in 2023. This stability suggests that market demand and population growth might be balanced by market saturation and competitive pricing. The year-on-year growth from 2024 indicates a modest rise, but the 5-year compound average growth rate demonstrates little to no variation, revealing a plateau in sales projections.

Future trends to watch for include advancements in personalized medicine, shifts in healthcare regulations, and the potential impact of new drug entrants or generic alternatives, which could affect market dynamics significantly.

Download as XLS

More about Antihypertensive Industry 2025-2029